J1 1lr2648

By: Delegate Arikan

Introduced and read first time: February 2, 2021 Assigned to: Health and Government Operations

## A BILL ENTITLED

1 AN ACT concerning

2

## Workgroup on Medical Cannabis Use by Pregnant and Nursing Women

- 3 FOR the purpose of establishing the Workgroup on Medical Cannabis Use by Pregnant and 4 Nursing Women; providing for the composition, chair, and staffing of the Workgroup; 5 prohibiting a member of the Workgroup from receiving certain compensation, but 6 authorizing the reimbursement of certain expenses; requiring the Workgroup to 7 conduct a certain study and make certain recommendations; requiring the 8 Workgroup to report its findings and recommendations to the Governor and the 9 General Assembly on or before a certain date; providing for the termination of this Act; and generally relating to the Workgroup on Medical Cannabis Use by Pregnant 10 11 and Nursing Women.
- 12 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF MARYLAND, 13 That:
- 14 (a) There is a Workgroup on Medical Cannabis Use by Pregnant and Nursing
- 15 Women.
- 16 (b) The Workgroup shall consist of the following members:
- 17 (1) two members of the Senate of Maryland, appointed by the President of 18 the Senate;
- 19 (2) two members of the House of Delegates, appointed by the Speaker of 20 the House;
- 21 (3) the Secretary of Health, or the Secretary's designee;
- 22 (4) the Executive Director of the Natalie M. LaPrade Medical Cannabis 23 Commission, or the Executive Director's designee; and



## HOUSE BILL 925

1		(5)	the following members, appointed by the Secretary of Health:
2			(i) one certifying provider of medical cannabis;
3			(ii) one licensed psychologist;
4			(iii) one child welfare expert;
5 6	physiologica	ıl effec	(iv) one member of the research community with expertise in the ts of medical cannabis; and
7 8	fulfill the du	uties of	(v) any other stakeholder considered necessary by the Secretary to the Workgroup.
9	(c)	The S	Secretary of Health shall designate the chair of the Workgroup.
10	(d)	The I	Maryland Department of Health shall provide staff for the Workgroup.
11	(e)	A me	mber of the Workgroup:
12		(1)	may not receive compensation as a member of the Workgroup; but
13 14	Travel Regu	(2) ılation	is entitled to reimbursement for expenses under the Standard States, as provided in the State budget.
15	(f)	The V	Workgroup shall:
16		(1)	study:
17 18 19			(i) how to conduct drug testing to ensure that an individual is not nnabis user if the individual uses only over—the—counter cannabidiol ng no tetrahydrocannabinol (THC);
20 21	unnecessary	y Child	(ii) the psychological and bonding effects on mother and baby of Protective Services investigations;
22 23	the conditio	ns for	(iii) the conditions for which medical cannabis is administered and which a pregnant or nursing woman may use medical cannabis;
24 25 26	compared to woman;	othei	(iv) the comparative effects of medical cannabis on a fetus as medications used to treat the same medical conditions in a pregnant
27 28 29	compared to mother;	o othe	(v) the comparative effects of medical cannabis on a nursing child as medications used to treat the same medical conditions in a nursing

- 1 (vi) the impact of the cessation of usage of medical cannabis on a 2 pregnant woman and her fetus; and
- 3 (vii) the impact of the cessation of usage of medical cannabis on a 4 nursing mother and the nursing child; and
- 5 (2) make recommendations regarding guidelines for medical cannabis 6 exposure for pregnant and nursing women.
- 7 (g) On or before December 31, 2021, the Workgroup shall report its findings and 8 recommendations to the Governor and, in accordance with § 2–1257 of the State 9 Government Article, the General Assembly.
- SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect June 1, 2021. It shall remain effective for a period of 1 year and 1 month, and, at the end of June 30, 2022, this Act, with no further action required by the General Assembly, shall be abrogated and of no further force and effect.